Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 2, 2018New England Journal of MedicineOpen Access

Durable Remissions with Ivosidenib in IDH1 -Mutated Relapsed or Refractory AML

View Full Paper
Ask AI
Bookmark
Share

Authors

CDCourtney D. DiNardoThe University of Texas MD Anderson Cancer CenterESEytan M. SteinMemorial Sloan Kettering Cancer CenterSBStéphane de BottonUniversité de Lille

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

DiNardo et al. (2018) studied this question.

synapsesocial.com/papers/69d7529a447a5ff6a2b8a5f2https://doi.org/10.1056/nejmoa1716984
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Acute Myeloid Leukemia With <i>IDH1</i> or <i>IDH2</i> Mutation2010 · 177 citations
  2. 2Transforming single DNA molecules into fluorescent magnetic particles for detection and enumeration of genetic variations2003 · 839 citations
  3. 3Correlation Between Isocitrate Dehydrogenase Gene Aberrations and Prognosis of Patients with Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis2017 · 107 citations
  4. 4Discovery of AG-120 (Ivosidenib): A First-in-Class Mutant IDH1 Inhibitor for the Treatment of IDH1 Mutant Cancers2018 · 453 citations
  5. 5Differentiation Syndrome Associated With Enasidenib, a Selective Inhibitor of Mutant Isocitrate Dehydrogenase 22018 · 196 citations